{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:09:00Z","timestamp":1794852540179,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sarcoptic mange is a common, pruritic parasitic skin disease of dogs. Due to its highly contagious character, it represents a potential veterinary and public health risk. Because of clinical similarity with other diseases, cross-antigenicity, and low sensitivity of available diagnostic methods, therapeutical trial is frequently used to confirm the disease. Considering the variety of available acaricidal molecules as well as the need to use the most effective treatment, the present paper reviews evidence comparing different types of systemic treatment of canine scabies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Analysis of the results showed that afoxolaner, fluralaner and sarolaner as well as several macrocyclic lactones such as selamectin, moxidectin and milbemycin oxime can lead to parasitological and clinical cure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The similarity in the clinical and parasitological efficacy of these substances enhances the need for comparative studies, which could\u00a0allow the identification of the most efficacious product.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-023-03759-1","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T08:01:39Z","timestamp":1696492899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The most effective systemic treatment in dogs with sarcoptic mange: a critically appraised topic"],"prefix":"10.1186","volume":"19","author":[{"given":"Mirabela O.","family":"Dumitrache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Cadiergues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"3759_CR1","first-page":"284","volume-title":"Muller and Kirk\u2019s Small Animal Dermatology","author":"WH Miller Jr","year":"2012","unstructured":"Miller WH Jr, Griffin CE, Campbell KL. Parasitic skin diseases. In: Mosby E, editor. Muller and Kirk\u2019s Small Animal Dermatology. 7th ed. St Louis: Saunders; 2012. p. 284\u2013342.","edition":"7"},{"issue":"1","key":"3759_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13071-017-2234-1","volume":"10","author":"LG Arlian","year":"2017","unstructured":"Arlian LG, Morgan MS. A review of Sarcoptes scabiei: past, present and future. Parasit Vectors. 2017;10(1):297.","journal-title":"Parasit Vectors"},{"issue":"1","key":"3759_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s13071-020-04395-6","volume":"13","author":"R Chiummo","year":"2020","unstructured":"Chiummo R, Petersen I, Plehn C, Zschiesche E, Roepke R, Thomas E. Efficacy of orally and topically administered fluralaner (Bravecto((R))) for treatment of client-owned dogs with sarcoptic mange under field conditions. Parasit Vectors. 2020;13(1):524.","journal-title":"Parasit Vectors"},{"issue":"5","key":"3759_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/vde.12363","volume":"27","author":"C Romero","year":"2016","unstructured":"Romero C, Heredia R, Pineda J, Serrano JA, Mendoza GD, Trapala P, Cordero AM. Efficacy of fluralaner in 17 dogs with sarcoptic mange. Vet Dermatol. 2016;27(5):353-e388.","journal-title":"Vet Dermatol"},{"key":"3759_CR5","first-page":"6639017","volume":"2021","author":"F Moog","year":"2021","unstructured":"Moog F, Brun J, Bourdeau P, Cadiergues MC. Clinical, parasitological, and serological follow-up of dogs with sarcoptic mange treated orally with lotilaner. Case Rep Vet Med. 2021;2021:6639017.","journal-title":"Case Rep Vet Med"},{"issue":"6","key":"3759_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.0959-4493.2001.00265.x","volume":"12","author":"KS Lower","year":"2001","unstructured":"Lower KS, Medleau LM, Hnilica K, Bigler B. Evaluation of an enzyme-linked immunosorbent assay (ELISA) for the serological diagnosis of sarcoptic mange in dogs. Vet Dermatol. 2001;12(6):315\u201320.","journal-title":"Vet Dermatol"},{"key":"3759_CR7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"6","key":"3759_CR8","first-page":"1201","volume":"45","author":"VJ Scheidt","year":"1984","unstructured":"Scheidt VJ, Medleau L, Seward RL, Schwartzman RM. An evaluation of ivermectin in the treatment of sarcoptic mange in dogs. Am J Vet Res. 1984;45(6):1201\u20132.","journal-title":"Am J Vet Res"},{"issue":"4","key":"3759_CR9","first-page":"219","volume":"37","author":"WH Miller Jr","year":"1996","unstructured":"Miller WH Jr, de Jaham C, Scott DW, Cayatte SM, Bagladi MS, Buerger RG. Treatment of canine scabies with milbemycin oxime. Can Vet J. 1996;37(4):219\u201321.","journal-title":"Can Vet J"},{"issue":"6","key":"3759_CR10","first-page":"379","volume":"38","author":"M Paradis","year":"1997","unstructured":"Paradis M, de Jaham C, Page N. Topical (pour-on) ivermectin in the treatment of canine scabies. Can Vet J. 1997;38(6):379\u201382.","journal-title":"Can Vet J"},{"issue":"3\u20134","key":"3759_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0304-4017(00)00298-3","volume":"91","author":"DJ Shanks","year":"2000","unstructured":"Shanks DJ, McTier TL, Behan S, Pengo G, Genchi C, Bowman DD, Holbert MS, Smith DG, Jernigan AD, Rowan TG. The efficacy of selamectin in the treatment of naturally acquired infestations of Sarcoptes scabiei on dogs. Vet Parasitol. 2000;91(3\u20134):269\u201381.","journal-title":"Vet Parasitol"},{"issue":"3\u20134","key":"3759_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0304-4017(00)00300-9","volume":"91","author":"RH Six","year":"2000","unstructured":"Six RH, Clemence RG, Thomas CA, Behan S, Boy MG, Watson P, Benchaoui HA, Clements PJ, Rowan TG, Jernigan AD. Efficacy and safety of selamectin against Sarcoptes scabiei on dogs and Otodectes cynotis on dogs and cats presented as veterinary patients. Vet Parasitol. 2000;91(3\u20134):291\u2013309.","journal-title":"Vet Parasitol"},{"issue":"2","key":"3759_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-4017(00)00357-5","volume":"93","author":"R Wagner","year":"2000","unstructured":"Wagner R, Wendlberger U. Field efficacy of moxidectin in dogs and rabbits naturally infested with Sarcoptes spp., Demodex spp and Psoroptes spp. mites. Vet Parasitol. 2000;93(2):149\u201358.","journal-title":"Vet Parasitol"},{"issue":"Suppl 1","key":"3759_CR14","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1007\/s00436-005-1449-9","volume":"97","author":"K Krieger","year":"2005","unstructured":"Krieger K, Heine J, Dumont P, Hellmann K. Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study. Parasitol Res. 2005;97(Suppl 1):S81\u20138.","journal-title":"Parasitol Res"},{"issue":"1\u20132","key":"3759_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1751-0813.2006.tb13117.x","volume":"84","author":"LJ Fourie","year":"2006","unstructured":"Fourie LJ, Heine J, Horak IG. The efficacy of an imidacloprid\/moxidectin combination against naturally acquired Sarcoptes scabiei infestations on dogs. Aust Vet J. 2006;84(1\u20132):17\u201321.","journal-title":"Aust Vet J"},{"issue":"4","key":"3759_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11259-011-9468-8","volume":"35","author":"SK Behera","year":"2011","unstructured":"Behera SK, Dimri U, Singh SK, Mohanta RK. The curative and antioxidative efficiency of ivermectin and ivermectin + vitamin E-selenium treatment on canine Sarcoptes scabiei infestation. Vet Res Commun. 2011;35(4):237\u201344.","journal-title":"Vet Res Commun"},{"key":"3759_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.vetpar.2016.02.017","volume":"222","author":"C Becskei","year":"2016","unstructured":"Becskei C, De Bock F, Illambas J, Cherni JA, Fourie JJ, Lane M, Mahabir SP, Six RH. Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica), for the treatment of sarcoptic mange in dogs. Vet Parasitol. 2016;222:56\u201361.","journal-title":"Vet Parasitol"},{"key":"3759_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1051\/parasite\/2016026","volume":"23","author":"F Beugnet","year":"2016","unstructured":"Beugnet F, de Vos C, Liebenberg J, Halos L, Larsen D, Fourie J. Efficacy of afoxolaner in a clinical field study in dogs naturally infested with Sarcoptes scabiei. Parasite. 2016;23:26.","journal-title":"Parasite"},{"issue":"1","key":"3759_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s13071-016-1670-7","volume":"9","author":"J Taenzler","year":"2016","unstructured":"Taenzler J, Liebenberg J, Roepke RK, Frenais R, Heckeroth AR. Efficacy of fluralaner administered either orally or topically for the treatment of naturally acquired Sarcoptes scabiei var. canis infestation in dogs. Parasit Vectors. 2016;9(1):392.","journal-title":"Parasit Vectors"},{"key":"3759_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1051\/parasite\/2018064","volume":"25","author":"V Hampel","year":"2018","unstructured":"Hampel V, Knaus M, Schafer J, Beugnet F, Rehbein S. Treatment of canine sarcoptic mange with afoxolaner (NexGard((R))) and afoxolaner plus milbemycin oxime (NexGard Spectra((R))) chewable tablets: efficacy under field conditions in Portugal and Germany. Parasite. 2018;25:63.","journal-title":"Parasite"},{"issue":"3","key":"3759_CR21","first-page":"212","volume":"84","author":"C Romero-Nunez","year":"2020","unstructured":"Romero-Nunez C, Bautista-Gomez LG, Sheinberg G, Martin-Cordero A, Flores-Ortega A, Heredia-Cardenas R. Efficacy of afoxolaner plus milbemycin oxime and afoxolaner alone as treatment for sarcoptic mange in naturally infested dogs. Can J Vet Res. 2020;84(3):212\u20136.","journal-title":"Can J Vet Res"},{"issue":"6","key":"3759_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1365-3164.2010.00895.x","volume":"21","author":"Y Terada","year":"2010","unstructured":"Terada Y, Murayama N, Ikemura H, Morita T, Nagata M. Sarcoptes scabiei var. canis refractory to ivermectin treatment in two dogs. Vet Dermatol. 2010;21(6):608\u201312.","journal-title":"Vet Dermatol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-023-03759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-023-03759-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-023-03759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:23:26Z","timestamp":1700583806000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-023-03759-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3759"],"URL":"https:\/\/doi.org\/10.1186\/s12917-023-03759-1","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.O.D. declares no conflict of interest. Over the past five years, M.-C.C. has received research support and lecturing honorarium from Elanco, Virbac and Zoetis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}